Skip to main content
MLEC
NASDAQ Manufacturing

Moolec Science Secures Nasdaq Exception, Boosts Equity by Over $100M via Subsidiary Derecognition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$6.6
Mkt Cap
$4.705M
52W Low
$3.077
52W High
$157.05
52W Position info
115% above low
Off High info
96% below high
Rel. Volume info
19× avg
Market data snapshot near publication time

MLEC has more than doubled off its 52-week low of $3.077 on elevated volume (19× avg).

Summary

Moolec Science SA has received an exception from Nasdaq until June 29, 2026, to regain compliance with listing requirements, reporting an estimated increase of over $100 million in stockholders' equity due to the derecognition of bankrupt subsidiaries.


Key Events · Corporate Governance and Compliance · MLEC

  • Nasdaq Compliance Exception

    Moolec Science SA received an exception from the Nasdaq Hearings Panel until June 29, 2026, to regain compliance with the stockholders' equity requirement, mitigating immediate delisting concerns.

  • Significant Equity Increase

    The company reported an estimated increase of approximately $100.8 million in stockholders' equity, which it believes brings it into compliance with Nasdaq's listing rules.

  • Derecognition of Bankrupt Subsidiaries

    This equity increase stems from accounting gains recognized due to the loss of control over subsidiaries Bioceres S.A., Bioceres LLC, and Theo I SCSp, following their bankruptcy proceedings in December 2025.


Analysis · MLEC · Manufacturing

The Nasdaq Hearings Panel granted Moolec Science an exception, extending its deadline to meet the stockholders' equity requirement until June 29, 2026. This temporary relief from potential delisting is a critical development for the company. Moolec believes it has already regained compliance, attributing an estimated $100.8 million increase in stockholders' equity to accounting gains from the derecognition of subsidiaries (Bioceres S.A., Bioceres LLC, and Theo I SCSp) following their respective bankruptcy proceedings. While the underlying bankruptcies of subsidiaries are negative operational events, the resulting accounting gains significantly improve Moolec's balance sheet and address a key listing compliance issue, providing a positive signal for the company's immediate future on Nasdaq.

At the time of this filing, MLEC was trading at $6.60 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $3.08 to $157.05. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLEC - Latest Insights

MLEC
Jul 13, 2026, 7:16 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $7.66
Real-time Price: $7.72 info
Change: +$0.0551 (+0.72%) info
Market Cap: $5.275M info
MLEC
Jun 02, 2026, 8:45 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $7.00
Real-time Price: $7.72 info
Change: +$0.7151 (+10%) info
Market Cap: $5.275M info
MLEC
May 14, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
7
Price at Filing: $8.62
Real-time Price: $7.72 info
Change: -$0.9049 (-10%) info
Market Cap: $5.275M info
MLEC
May 13, 2026, 9:17 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $9.00
Real-time Price: $7.72 info
Change: -$1.28 (-14%) info
Market Cap: $5.275M info
MLEC
May 13, 2026, 5:19 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.34
Real-time Price: $7.72 info
Change: -$0.6249 (-7%) info
Market Cap: $5.275M info